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Antibody-driven psychosis
Psychotic episodes in lupus patients can be triggered by an antibody attack 
on brain cells, according to Matus et al. (page 3221).
The psychosis that occurs in a small subset of lupus patients is associated 
with an antibody that recognizes a trio of ribosomal phosphoproteins. It 
was assumed that this antibody binds to the cell surface version of one of 
the phosphoproteins and somehow penetrates cells to cause damage. But 
how the interaction between the antibody and its targets leads to a 
breakdown in neuronal function was a mystery.
Matus et al. now find that the antibody also recognizes a novel, nonribo-
somal protein on the surface of neurons. In rat brains, this protein was con-
centrated in regions that control cognition and emotion—the functions that 
go awry during lupus-related psychosis. Treating cultured neurons with the 
antibody or injecting it directly into rat brains caused increased intracellular 
calcium levels, thereby causing neuronal death. The kind of ion channel 
opened by antibody binding and the mechanism involved is still unknown.
The team also found these antibodies in lupus patients who showed 
no signs of psychosis. Antibodies that attack neurons can only cause 
damage if they are allowed to sneak through a breach in the blood–brain 
barrier. The authors therefore suspect that only patients who for some 
reason have such a breach experience the psychosis.
The function of the neuronal surface protein is unknown. Its associations 
with clathrin and protein domains that are characteristic of ubiquitin ligases 
suggest that this protein may regulate the trafficking and degradation 
of surface receptors in neurons. HB
Antibodies, hold the light chain
Antibodies don’t always need light chains to 
function, according to Zou et al. (page 3271).
In mammalian antibodies, two heavy chains link 
together to form a Y-shaped complex, with each 
arm of the Y linked to a light chain. In mice and 
humans, lone heavy chains are usually prevented 
from being secreted by a chaperone that associates 
with the heavy chain’s constant region—the same 
region that links to the light chain. But the new 
report shows that an unusual set of fully functional 
heavy chain–only antibodies do get secreted.
The anomalous antibodies escaped to the cell 
surface because they lacked the chaperone-binding region. The secretion of 
these antibodies was discovered in mutant mice that lack light chain genes, 
but the authors also found that smaller amounts were produced in the 
spleen of normal mice, probably as a result of gene deletion errors during 
B cell development. The odd antibodies appeared to bind antigen normally 
and display the normal range of heavy chain diversity.
The discovery has precedence—camels and their relatives produce heavy 
chain–only antibodies in abundance. Light chain–deficient mice might allow 
the ready production of heavy chain–only monoclonal antibodies, whose 
smaller size lets them recognize antigen structures that elude standard 
antibodies. Humans might also make these antibodies in small amounts, but 
their relevance in vivo remains a mystery. RR
Choking on 
mitochondria
In patients with asthma, airway smooth muscle 
cells make too many mitochondria, say 
Trian et al. on page 3173. Instead of easing 
breathing, these mitochondrial masses trigger 
cell division, leading to a choking build-up of 
smooth muscle cells.
Many chronic lung diseases, such as asthma 
and chronic obstructive pulmonary disease 
(COPD), are characterized by an increased 
mass of smooth muscle in the bronchi, which 
causes the airways to constrict. Although 
bronchial dilators ease acute asthma attacks, 
they have no effect on the muscle build-up.
In patients with asthma, these muscle cells 
were known to divide excessively, but what 
prompted this cell division was unclear. Trian 
et al. now show that an overdose of calcium 
influx triggers the expression of mitochondria-
building transcription factors in the cells.
The resulting construction of new mito-
chondria—and subsequent burst in ATP pro-
duction—gave the cells the energy boost needed 
for proliferation. This pathway was specific to 
patients with asthma, as mitochondria numbers 
and activity were not increased in cells from 
patients with COPD. Smooth muscle cell pro-
liferation in COPD patients, by contrast, was 
driven by anaerobic glycolysis.
Calcium channel blockers, which have 
been shown to relieve asthma attacks and 
block tumor cell proliferation, might thus also 
reverse the smooth muscle cell accumulation 
that perpetuates chronic disease. RR
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